Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Retained Earnings (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Retained Earnings for 12 consecutive years, with $61000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 771.43% to $61000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61000.0 through Dec 2025, up 771.43% year-over-year, with the annual reading at $61000.0 for FY2025, 771.43% up from the prior year.
  • Retained Earnings for Q4 2025 was $61000.0 at Theravance Biopharma, up from -$920.7 million in the prior quarter.
  • The five-year high for Retained Earnings was $61000.0 in Q4 2025, with the low at -$1.8 billion in Q2 2022.
  • Average Retained Earnings over 5 years is -$712.6 million, with a median of -$883.8 million recorded in 2023.
  • The sharpest move saw Retained Earnings plummeted 22002350.0% in 2022, then soared 771.43% in 2025.
  • Over 5 years, Retained Earnings stood at -$1.7 billion in 2021, then skyrocketed by 100.0% to -$15000.0 in 2022, then plummeted by 333.33% to -$65000.0 in 2023, then skyrocketed by 110.77% to $7000.0 in 2024, then skyrocketed by 771.43% to $61000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $61000.0, -$920.7 million, and -$10000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.